Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Swipe the table sideways to see every compound.
| Attribute |  |
|---|---|
| Category | Metabolic |
| Evidence grade | A Human trial evidence |
| Regulatory status | FDA-approved |
| Human amounts | FDA labelDosing reference Study durations |
| Format | Lyophilized vial |
| Type | Single compound |
| Molecular formula | C172H265N43O51 |
| Molecular weight | 3,751 g/mol |
| CAS number | Not listed |
| Sequence | Not listed |
| References | 7 |
| Summary | Liraglutide is a once-daily GLP-1 receptor agonist that is approved by the FDA for type 2 diabetes and cardiovascular risk reduction (Victoza) and for chronic weight management (Saxenda). It is shorter acting than the once-weekly agents semaglutide and tirzepatide, with a half-life of about 13 hours. This entry summarizes the FDA labels and pivotal published trials for research reference only. |